Pomerantz LLP has filed a class action lawsuit against Replimune Group following the FDA's rejection of its Biologics License Application for the cancer drug RP1 combined with nivolumab. The FDA cited multiple deficiencies in Replimune's clinical trials and found insufficient evidence of the drug's effectiveness, leading to a sharp drop in the company's stock price. The lawsuit alleges securities fraud and other unlawful practices by Replimune and its executives. Investors who purchased Replimune securities during the class period can seek lead plaintiff status until October 5, 2026.
Designer Brands Inc. reported Q2 earnings of $0.34 per share, beating estimates by 36%, but revenue fell 1.2% year-over-year to $730.63 million, missing expectations. The company improved profitability with an expanded adjusted gross margin of 47.9%,...
The Lovesac Company reported a better-than-expected Q2 earnings per share (EPS) of -$0.35, beating estimates by over 10% and improving from a -$0.45 loss a year ago. Despite this EPS beat, the company's revenue of $161.25 million narrowly missed anal...
Copart, Inc. is set to report its Q3 earnings with analysts expecting an EPS of $0.38, down from $0.41 last year, while revenue is projected to increase slightly to $1.14 billion from $1.13 billion. The company faces headwinds from a weak US market a...
Agree Realty Director Rakolta has purchased 20,136 shares of the company, investing approximately $1.5 million. This insider buying could signal confidence in the company's future prospects. Investors may view this as a positive sign, potentially imp...
MasterCraft Boat Holdings reported Q4 earnings of $0.67 per share, surpassing analyst estimates of $0.61 and up from $0.40 a year ago. Revenue reached $129.94 million, well above the expected $93.05 million. The company maintains a strong current rat...
